Compare organizations

Baxter is a global healthcare company with a leading portfolio of critical care, nutrition, renal, hospital and surgical products and we are driven by our mission to save and sustain lives. We stand ready to partner with EU policy-makers during the on-going process to modernise the EU’s regulatory environment for pharmaceuticals.

EFCG, the European Fine Chemicals Group, represents European manufacturers of APIs, excipients and fine chemicals. As producers of the essential building blocks used to make medicines, we welcome the Commission’s initiative to ensure a future-proof and crisis-resistant medicines regulatory system that will allow all EU citizens full and equal access to safe, state-of-the-art therapies.

Response from the European Fluorocarbons Technical Committee (EFCTC) to the Inception Impact Assessment on the revision of Regulation No. 517/2014 (Ref. Ares (2020) 3402178 - 29/06/2020) is detailed in the attached document. While contributing to this consultation we remain very aware we are all still experiencing unprecedented times. As Cefic, we aim to maintain a high standard in our responses.

Baxter is a leading global pharmaceutical & medical device company committed to delivering life-saving and sustaining products. We have been working with clinicians and hospitals across Europe for years to provide anaesthetic agents (inhaled & intravenous) that allow clinical treatment to be tailored to specific patient needs.

EFCTC representing fluorocarbons manufacturers fully supports the objectives of the F-gas Regulation to encourage transition to lower GWP refrigerants. Our industry remains committed to do its part to comply with the already ambitious phasedown schedule for HFCs.